Computer Manufacturing Employees and Cancer Risk

Cancer-related mortality is considerably higher among people who work in computer manufacturing industry, says a report in the journal Environmental Health.



Similar findings have been reported among employees who work in plants that manufacture computers, semiconductors, integrated circuits and other components, Dr. Richard W. Clapp, an epidemiologist at Boston University School of Public Health, has found.



"When comparing four plants around the country, the findings were remarkably similar, in revealing excess cancers of the brain, non-Hodgkin's lymphoma, and kidney, primarily among manufacturing workers," says Dr. Clapp.



There were also excessive numbers of deaths due to multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis, the study shows.



Among the reasons for this morbid statistics, Dr. Clapp lists the routine routinely exposure of workers to carcinogenic substances such as solvents and chemicals such as photoresist, metals, such as arsenic, nickel and chromium, electromagnetic fields, especially ultraviolet light, radio frequency, and X-ray radiation.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap